Year: 2013
Type: article
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by alloreactive donor T-cell-mediated graft-versus-host disease (GvHD). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG), is an inhibitor of both DNA methyltransferase 1 (DNMT1) and signal transducer and activator of transcription 1 (STAT1), which are essential for induction of GvHD. Thus, in this report, we examine if in vivo administration of EGCG mitigates GvHD in several different animal models. While we concede that refinement of EGCG treatment might result in GvHD prevention, our results suggest that EGCG treatment might not be an effective therapy against GvHD in the clinic.
Source: Cell Transplantation
Institution: Washington University in St. Louis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: National Cancer Institute
Awards: OPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADE, Genetic Manipulation of T Cells--PreClinical Models, WU-MDACC Inter-Institutional Molecular Imaging Center, TARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AML, DLI using genetically modified T cells: Phase 1 trial, Genomics Of Acute Myeloid Leukemia., Cancer Center Support Grant
OpenAlex ID: W2069282861